US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

BriaCell Therapeutics Corp. Warrant

0.0700

0.0000

Volume:- -

Turnover:286.32

Market Cap:- -

PE:- -

High:0.0700

Open:0.0700

Low:0.0700

Close:0.0700

Loading ...

Overview Company News Filings

Briacell Bria-Ots™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination With Checkpoint Inhibitor

THOMSON REUTERS

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

BRIEF-Briacell Therapeutics Announces Closing Of $13.8 Million Public Offering

Briacell Therapeutics Announces Closing of $13.8 Million Public Offering

THOMSON REUTERS

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

BRIEF-Briacell Therapeutics Says Units Priced At $4.50 Each For Gross Proceeds Of $13.8 Million

Briacell Therapeutics Corp - Units Priced at $4.50 Each for Gross Proceeds of $13.8 Million

THOMSON REUTERS

Briacell Therapeutics Announces Pricing of $13.8 Million Public Offering

THOMSON REUTERS

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

BriaCell Jumps 41% in U.S. Pre-market Trading, Reports Complete Lung Metastasis Resolution in Patient

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

Briacell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-Abc)

THOMSON REUTERS

BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)

BRIEF-Briacell Phase 2 Survival Data Beats Leading Standard In Hr+ Breast Cancer

Briacell Therapeutics Corp - No Bria-Imt Related Discontinuations Reported to Date

THOMSON REUTERS

Briacell Therapeutics Corp - Bria-Imt Survival Data in Tnbc Patients Comparable to Trodelvy

THOMSON REUTERS

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

Briacell Therapeutics Corp - Briapro to Develop Anti-B7-H3 Antibodies for Multiple Cancer Indications

THOMSON REUTERS

BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BCTXW/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCTXW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCTXW\",,,,,undefined,":{"symbol":"BCTXW","market":"US","secType":"STK","nameCN":"BriaCell Therapeutics Corp. Warrant","latestPrice":0.07,"timestamp":1749482310120,"preClose":0.07,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"06-09 11:18:30 EDT","open":0.07,"high":0.07,"low":0.07,"amount":286.3215037,"amplitude":0,"askPrice":0.099,"askSize":100,"bidPrice":0.063,"bidSize":100,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1749499200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":0.07,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCTXW\",,,,,undefined,":{"symbol":"BCTXW","floatShares":0,"roa":"-158.14%","roe":"-536.81%","lyrEps":0,"shares":0,"dividePrice":0,"high":0.07,"amplitude":0,"preClose":0.07,"low":0.07,"week52Low":0.0238,"pbRate":"0.00","week52High":0.7,"institutionHeld":0,"latestPrice":0.07,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0.07,"prevYearClose":0.2895,"prevWeekClose":0.07,"prevMonthClose":0.09,"prevQuarterClose":0.1019,"fiveDayClose":0.106,"twentyDayClose":0.065,"sixtyDayClose":0.1046},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCTXW\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2538646390","title":"Briacell Bria-Ots™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination With Checkpoint Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2538646390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538646390?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:30","pubTimestamp":1748345415,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nTUA4W9XSN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXW"],"gpt_icon":0},{"id":"2531303571","title":"BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified","url":"https://stock-news.laohu8.com/highlight/detail?id=2531303571","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531303571?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:30","pubTimestamp":1746012600,"startTime":"0","endTime":"0","summary":"Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 study. Biomarkers could be utilized to predict and provide better patient outcomes, including response rates and survival benefits. Positive delayed-type hypersensitivity   and a favorable Neutrophil-to-Lymphocyte Ratio   linked to longer progression-free survival  in Phase 3 patients. Presence of Circulating Tumor Cells  after patients’ initial Phase 3 treatment supports role as negative prognostic marker . Bria-IMT Phase 3 regimen was well-tolerated with a preferred tolerability profile. “Using biomarkers as powerful instruments to predict patient responsiveness to the Bria-IMT treatment would allow physicians and oncologists to identify potential responders sooner, providing better clinical outcomes and ultimately extending patients’ lives,” stated Carmen Calfa, MD, Clinical Research Lead for the breast site disease group at the University of Miami Miller School of Medicin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-reports-breaker-phase-3-113000083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAML","PFS","BK4139","TPC","BCTX","NLR","BK4129","BCTXZ","BCTXW","OS","DTH","BK4097","BK4211","BK4195","BK4606"],"gpt_icon":0},{"id":"2531268661","title":"BRIEF-Briacell Therapeutics Announces Closing Of $13.8 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2531268661","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531268661?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:10","pubTimestamp":1745871023,"startTime":"0","endTime":"0","summary":"BRIEF-Briacell Therapeutics Announces Closing Of $13.8 Million Public OfferingApril 28 (Reuters) - Briacell Therapeutics Corp BCT.TO:BRIACELL THERAPEUTICS ANNOUNCES CLOSING OF $13.8 MILLION PUBLIC OFFERINGSource text: ID:nGNX96m6J2Further company coverage: BCT.TO (Reuters.Briefs@thomsonreuters.com)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nTUA61CKJD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTXW"],"gpt_icon":0},{"id":"2531526885","title":"Briacell Therapeutics Announces Closing of $13.8 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2531526885","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531526885?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:05","pubTimestamp":1745870714,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nTUA61CKJD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXW"],"gpt_icon":0},{"id":"2531263564","title":"BriaCell Therapeutics Announces Closing of $13.8 million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2531263564","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531263564?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:05","pubTimestamp":1745870700,"startTime":"0","endTime":"0","summary":"PHILADELPHIA and VANCOUVER, British Columbia, April 28, 2025  -- BriaCell Therapeutics Corp.   , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced underwritten public offering of 3,066,666 units, including 399,999 units sold upon the full exercise of the underwriter’s option to purchase additional units. Each unit consists of one common share  and one warrant . Each unit was sold to the public at a price of $4.50 per unit  for gross proceeds of approximately $13.8 million, before deducting underwriting discounts and offering expenses. The Warrants included in the units were approved for listing on the Nasdaq Capital Market and commenced trading under the symbol “BCTXZ” on April 25, 2025. Each Warrant is immediately exercisable, entitles the holder to purchase one common share at an exercise price of $5.25 per share and expires five years from the date of issuance. The Company is r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-therapeutics-announces-closing-13-200500270.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4139","BCTX","LENZ","BCTXW","BCTXZ"],"gpt_icon":0},{"id":"2530147098","title":"BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2530147098","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530147098?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:30","pubTimestamp":1745839800,"startTime":"0","endTime":"0","summary":"Overall survival and clinical benefit in Phase 2 continue to outperform historical benchmarks, including very heavily pretreated patients. Clinical benefit observed in 83% of evaluable patient sub-group treated with the phase 3 formulation. Improved new Bria-OTS+ platform provides powerful innate and adaptive immune system activation. Title:Survival outcomes in a randomized phase 2 ofBria-IMT: An allogeneic whole cell cancer vaccineSession Title:Phase II and Phase III Clinical TrialsSession Start:4/28/2025 2:00 PM – 5:00 PM CSTLocation:Poster Section 50Poster Board Number:18Abstract Presentation Number:CT100. “We are thrilled to share impressive survival and clinical efficacy data at AACR on the advantages of using Bria-IMT plus checkpoint inhibitor in heavily treated patients who have failed multiple prior treatments, including ADCs and CPIs,” stated lead author, Saranya Chumsri, MD, Principal Investigator and Professor of Oncology, Mayo Clinic. “Treatment options have been limited fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-presents-benchmark-beating-survival-113000613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ORR","BCTXZ","BK4139","BCTXW","BK4097","OS","BCTX"],"gpt_icon":0},{"id":"2530158959","title":"BRIEF-Briacell Therapeutics Says Units Priced At $4.50 Each For Gross Proceeds Of $13.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2530158959","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530158959?lang=en_us&edition=fundamental","pubTime":"2025-04-25 08:02","pubTimestamp":1745539337,"startTime":"0","endTime":"0","summary":"BRIEF-Briacell Therapeutics Says Units Priced At $4.50 Each For Gross Proceeds Of $13.8 MillionApril 24 (Reuters) - Briacell Therapeutics Corp BCT.TO:BRIACELL THERAPEUTICS ANNOUNCES PRICING OF $13.8 M","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nTUA1V7V76:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTXW"],"gpt_icon":0},{"id":"2530913033","title":"Briacell Therapeutics Corp - Units Priced at $4.50 Each for Gross Proceeds of $13.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2530913033","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530913033?lang=en_us&edition=fundamental","pubTime":"2025-04-25 08:00","pubTimestamp":1745539200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nTUA1V7V76:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXW"],"gpt_icon":0},{"id":"2530130369","title":"Briacell Therapeutics Announces Pricing of $13.8 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2530130369","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530130369?lang=en_us&edition=fundamental","pubTime":"2025-04-25 08:00","pubTimestamp":1745539200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nTUA1V7V76:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXW"],"gpt_icon":0},{"id":"2530163559","title":"BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2530163559","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530163559?lang=en_us&edition=fundamental","pubTime":"2025-04-25 08:00","pubTimestamp":1745539200,"startTime":"0","endTime":"0","summary":"PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025  -- BriaCell Therapeutics Corp.   , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of an underwritten public offering of 3,066,666 units, including 399,999 units sold upon the full exercise of the underwriter’s option to purchase additional units. Each unit consists of one common share  and one warrant . Each unit is being sold to the public at a price of $4.50 per unit  for gross proceeds of approximately $13.8 million, before deducting underwriting discounts and offering expenses. The Warrants included in the units have been approved for listing on the Nasdaq Capital Market and are expected to commence trading under the symbol “BCTXZ” on April 25, 2025. Each Warrant is immediately exercisable, and will entitle the holder to purchase one common share at an exercise price of $5.25 per share and will expire five years from the date of issuance. T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-therapeutics-announces-pricing-13-000000540.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCTX","LENZ","BCTXW","BK4007","BK4139"],"gpt_icon":0},{"id":"2529980343","title":"BriaCell Jumps 41% in U.S. Pre-market Trading, Reports Complete Lung Metastasis Resolution in Patient","url":"https://stock-news.laohu8.com/highlight/detail?id=2529980343","media":"MT Newswires","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529980343?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:43","pubTimestamp":1745498625,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics , up 41% in U.S. pre-market trading, on Thursday confirmed the sustained complete resolution of the lung metastasis, first reported in February, two months after initial treatment.The latest data at four months also demonstrates stable disease elsewhere, the company said.The patient, a 78-year-old woman with metastatic breast cancer, had failed several prior lines of therapy and received the lowest dose level in the Phase 1/2a Bria-OTS study. At enrollment last November, she had extensive metastases including bone, lymph node and lung involvement. Following Bria-OTS injections every two weeks for six weeks, and subsequent dosing every three weeks, the lung metastasis completely resolved with stable disease elsewhere. This response is now confirmed and shows the potentially promising activity of the Bria-OTS platform as monotherapy, Briacell said.\"This unprecedented anti-cancer response in the first patient dosed with Bria-OTS is an important milestone for us and p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-jumps-41-u-pre-124345885.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BriaCell Jumps 41% in U.S. Pre-market Trading, Reports Complete Lung Metastasis Resolution in Patient","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCTXW","BCTX","BK4139"],"gpt_icon":0},{"id":"2529983362","title":"BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™","url":"https://stock-news.laohu8.com/highlight/detail?id=2529983362","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529983362?lang=en_us&edition=fundamental","pubTime":"2025-04-24 19:30","pubTimestamp":1745494200,"startTime":"0","endTime":"0","summary":" Complete resolution of lung metastasis confirmed at 4 month follow-up in hormone receptor positive (HR+) breast cancer patient. Treatment well-tolerated and patient remains on study with stable disease elsewhere. Sustained clinical response supports Bria-OTS personalized, off-the-shelf immunotherapy approach in Phase 1/2a metastatic breast cancer study. PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025  -- BriaCell Therapeutics Corp.   , a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, confirms the sustained complete resolution of the lung metastasis, first reported in February 2025, two months after initial treatment in the ongoing Phase 1/2 Bria-OTS study. The latest data at four months also demonstrates stable disease elsewhere.Figure 1: Treatment with Bria-OTS monotherapy resulted in 100% resolution of tumor in the lung of the metastatic breast cancer  patient following 2 months of therapy and confirmed at 4 months of the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-confirms-100-resolution-lung-113000825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MBC","BK4139","BCTX","BK4086","BCTXW"],"gpt_icon":0},{"id":"2529377747","title":"Briacell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-Abc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2529377747","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529377747?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:30","pubTimestamp":1745321446,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUABBFDHT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXW"],"gpt_icon":0},{"id":"2529702493","title":"BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2529702493","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529702493?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:30","pubTimestamp":1745321400,"startTime":"0","endTime":"0","summary":"Over 75 patients enrolled in BriaCell’s pivotal Phase 3 study of Bria-IMT plus immune check point inhibitor in metastatic breast cancer . BriaCell’s pivotal Phase 3 clinical study is evaluating BriaCell’s lead clinical candidate, Bria-IMT, plus immune check point inhibitor versus physician’s choice in advanced metastatic breast cancer .About BriaCell’s Pivotal Phase 3 Clinical Study of Bria-IMT Combination Regimen in MBC patients. Interim data will be analyzed once 144 patient events  occur, comparing the overall survival  in patients treated with the Bria-IMT combination regimen versus those treated with physician’s choice as the primary endpoint. Positive results of the pivotal Phase 3 study could result in full approval and marketing authorization for Bria-IMT in MBC patients. BriaCell recently announced positive Phase 2 survival data in a similar MBC patient population treated with the same Bria-IMT combination regimen. The Bria-IMT combination regimen has received FDA Fast Track d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-enrollment-pace-accelerating-phase-113000724.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCTX","AEIS","BCTXW"],"gpt_icon":0},{"id":"2527903992","title":"BRIEF-Briacell Phase 2 Survival Data Beats Leading Standard In Hr+ Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527903992","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527903992?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:34","pubTimestamp":1744803262,"startTime":"0","endTime":"0","summary":"BRIEF-Briacell Phase 2 Survival Data Beats Leading Standard In Hr+ Breast CancerApril 16 (Reuters) - Briacell Therapeutics Corp BCT.TO:BRIACELL PHASE 2 SURVIVAL DATA BEATS LEADING STANDARD IN HR+ BREA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QU0Y8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTXW"],"gpt_icon":0},{"id":"2527829771","title":"Briacell Therapeutics Corp - No Bria-Imt Related Discontinuations Reported to Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2527829771","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527829771?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:30","pubTimestamp":1744803012,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QU0Y8:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXW"],"gpt_icon":0},{"id":"2527297796","title":"Briacell Therapeutics Corp - Bria-Imt Survival Data in Tnbc Patients Comparable to Trodelvy","url":"https://stock-news.laohu8.com/highlight/detail?id=2527297796","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527297796?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:30","pubTimestamp":1744803012,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QU0Y8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXW"],"gpt_icon":0},{"id":"2527202290","title":"BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527202290","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527202290?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:30","pubTimestamp":1744803000,"startTime":"0","endTime":"0","summary":"Median overall survival of 17.3 months in Bria-IMT treated patients with hormone receptor positive (HR+) metastatic breast cancer markedly exceeds historical data of 14.4 months in TRODELVY  in similar heavily pre-treated patients. Survival data in triple negative breast cancer patients treated with the BriaCell regimen was comparable to TRODELVY. PHILADELPHIA and VANCOUVER, British Columbia, April 16, 2025  -- BriaCell Therapeutics Corp.   , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data in its Phase 2 study of Bria-IMT plus check point inhibitors , outperforming ADC drugs in hormone receptor positive (HR+) metastatic breast cancer  patients.Table 1: Comparable Analysis of median overall survival  for the BriaCell Phase 2 study of BriaCell’s Bria-IMT plus CPI versus other drugs in MBC patient subsets","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-phase-2-survival-data-113000357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCTX","BK4124","BK4213","BK4203","BK4086","CPI","PR","SMP","MBC","BK4225","BCTXW","HR","BK4139"],"gpt_icon":0},{"id":"2526563392","title":"Briacell Therapeutics Corp - Briapro to Develop Anti-B7-H3 Antibodies for Multiple Cancer Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2526563392","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526563392?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:01","pubTimestamp":1744286482,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO0QK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXW"],"gpt_icon":0},{"id":"2522877526","title":"BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2522877526","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522877526?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:00","pubTimestamp":1742990400,"startTime":"0","endTime":"0","summary":"PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025  -- BriaCell Therapeutics Corp.   , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting three posters at the 2025 American Association for Cancer Research  Annual Meeting taking place from April 25th – 30th atMcCormick Place Convention Center, Chicago, IL. The details are listed below. The abstracts will be published in the online Proceedings of the AACR.Poster 1: Title: Bria-ABC1 vs physician choice in late-stage MBC; early biomarker correlates of the randomized registration trialSession Title: Late-Breaking Research: Clinical Research 4Session Date and Time: 4/30/2025 9:00 AM – 12:00 PM CSTLocation: Poster Section 49Poster Board Number: 14Abstract Presentation Number: LB408. Poster 2: Title: Survival outcomes in a randomized phase 2 of Bria-IMT: An allogeneic whole cell cancer vaccineSession Title: Phase II and Phase ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-present-clinical-preclinical-data-120000161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCTX","BCTXW","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCTXW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCTXW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCTXW\",market:\"US\",delay:false,,,undefined,":{}}}